MP
RNAC icon

Mangrove Partners’s Cartesian Therapeutics RNAC Stock Holding History

Mangrove Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-175,347
Closed -$5.94M – 264
2022
Q4 		$5.94M Hold
175,347
– – 0.34% 80
2022
Q3 		$8.63M Sell
175,347
-66,667
-28% -$3.66M 0.5% 60
2022
Q2 		$9.51M Buy
+242,014
New +$7.18M 0.47% 46
2021
Q1 		– Sell
-23,522
Closed -$2.14M – 324
2020
Q4 		$2.14M Sell
23,522
-169,364
-88% -$14.7M 0.29% 61
2020
Q3 		$9.49M Sell
192,886
-25,340
-12% -$1.94M 1.2% 24
2020
Q2 		$18.6M Buy
218,226
+33,264
+18% +$3.02M 4.54% 7
2020
Q1 		$13.4M Buy
184,962
+9,811
+6% +$947K 1.84% 17
2019
Q4 		$12.5M Buy
+175,151
New +$8.45M 1.83% 19

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mangrove Partners's RNAC Position: Q1 2023 in Review

Mangrove Partners sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 175,347 shares — an estimated $5.94M sold.

Mangrove Partners first reported a position in RNAC in Q4 2019 and held it in 8 quarters. The position peaked at $18.6M in Q2 2020. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • Mangrove Partners reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mangrove Partners sold 175,347 Cartesian Therapeutics shares in Q1 2023, an estimated $5.94M.
  • Mangrove Partners first reported a position in Cartesian Therapeutics in Q4 2019 and held it in 8 quarters.
  • Mangrove Partners's Cartesian Therapeutics position peaked at $18.6M in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Mangrove Partners's 13F filing for Q1 2023, filed 15 May 2023.